Lead Product(s) : Temtokibart
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
LEO Pharma Reports Positive Phase 2b Results for Temtokibart in Eczema
Details : LEO 138559 (temtokibart) is an investigational IL-22RA1 antagonist antibody candidate, which is being evaluated for the treatment of moderate-to-severe atopic dermatitis.
Product Name : LEO 138559
Product Type : Antibody
Upfront Cash : Inapplicable
May 09, 2025
Lead Product(s) : Temtokibart
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Orismilast
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
UNION Reports Phase 2b Results for Orismilast in Atopic Dermatitis, Confirming Efficacy
Details : UNI50001 (orismilast) is a next-generation, high-potency PDE4 inhibitor targeting the PDE4B/D subtypes. Currently, it is being evaluated for the treatment of Atopic Dermatitis.
Product Name : UNI50001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 25, 2024
Lead Product(s) : Orismilast
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Orismilast
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
UNION Completes Phase 2b Study of ADESOS, Data Presented at RAVE 2024
Details : UNI50001 (orismilast) is a potent PDE4B/D inhibitor, which is being investigated in adults with moderate-to-severe atopic dermatitis.
Product Name : UNI50001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 06, 2024
Lead Product(s) : Orismilast
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MC2-25 VLS
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MC2-25 VLS is a first-in-class drug candidate for urea associated skin diseases using a di-peptide as an iso-cyanate scavenger to inhibit carbamylation of amino acids and proteins in the skin.
Product Name : MC2-25 VLS
Product Type : Peptide
Upfront Cash : Inapplicable
November 23, 2023
Lead Product(s) : MC2-25 VLS
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Temtokibart
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Argenx
Deal Size : Inapplicable
Deal Type : Inapplicable
Temtokibart Achieves First Subject First Treatment (FSFT) Milestone in Phase 2b trial
Details : LEO 138559 (temtokibart) is an investigational monoclonal antibody that targets the IL-22RA1 receptor subunit, currently in Phase 2 development for the potential treatment of moderate-to-severe atopic dermatitis.
Product Name : LEO 138559
Product Type : Antibody
Upfront Cash : Inapplicable
November 10, 2023
Lead Product(s) : Temtokibart
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Argenx
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Orismilast
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : UNI50001 (orismilast), a high-potency PDE4 inhibitor linked to inflammation. Orismilast holds the potential to become a safe and efficacious oral treatment for many immunological diseases, and is currently developing oral orismilast for the treatment of ...
Product Name : UNI50001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 01, 2023
Lead Product(s) : Orismilast
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MC2-25 CKD
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MC2-25, a first-in-class di-peptide drug candidate functioning as an effective isocyanate scavenger, is presently undergoing Phase II clinical trial evaluation for the treatment of Chronic Kidney Disease-associated Pruritus.
Product Name : MC2-25 CKD
Product Type : Peptide
Upfront Cash : Inapplicable
July 12, 2023
Lead Product(s) : MC2-25 CKD
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Orismilast
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : UNI50001 (orismilast) is a high-potency, oral, next-generation PDE4 inhibitor targeting the PDE4 subtypes linked to inflammation, being developed in patients with hidradenitis suppurativa and also in atopic dermatitis (AD) and psoriasis.
Product Name : UNI50001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 21, 2023
Lead Product(s) : Orismilast
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Temtokibart
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LEO 138559 is an investigational monoclonal antibody which blocks the IL-22RA1 receptor subunit thereby inhibiting the effect of the interleukin-22 (IL-22) cytokine, it is currently being developed for the treatment of moderate-to-severe atopic dermatiti...
Product Name : LEO 138559
Product Type : Antibody
Upfront Cash : Inapplicable
March 18, 2023
Lead Product(s) : Temtokibart
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MC2-25
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MC2 Therapeutics Announces Initiation of a Phase 2 Clinical Trial in CKD-aP
Details : MC2-25 Cream is an effective isocyanate scavenger showing >90 % inhibition of protein carbamylation and counteracting the morphological skin changes induced by carbamylation as demonstrated in an in vitro reconstructed human uremic skin model.
Product Name : MC2-25
Product Type : Peptide
Upfront Cash : Inapplicable
September 14, 2022
Lead Product(s) : MC2-25
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable